President & CEO of Delphinus Medical Technologies, Mark leads a team that has succeeded in creating an innovative whole breast ultrasound imaging device called SoftVue that characterizes suspicious lesions for diagnostic applications using a safe (non-ionizing), comfortable (non-compressing), and reliable (operator independent) patented technology. Delphinus is a privately held medical technology company headquartered in Novi, Michigan and was founded in 2010 as a spin-off of the Barbara Ann Karmanos Cancer Institute (KCI).